Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine in the Treatment of Chronic Urticaria: Real-world Efficacy and Safety Study
ChiCTR2300068607Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Feb 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine in chronic idiopathic urticaria (CIU), symptomatic dermatographism (SD) and chronic urticaria (CU), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Urticaria activity score (UAS). Planned start Feb 2023; status: not yet recruiting.
02
Drugs
cyclosporine
03
Conditions
chronic idiopathic urticaria (CIU)symptomatic dermatographism (SD)chronic urticaria (CU)
Beyond the preview
Go deeper on ChiCTR2300068607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068607.